Relay Therapeutics Unveils Three New Programs at Event

Relay Therapeutics Inc., a clinical-stage precision medicine company, is set to unveil details of its innovative portfolio at the New Program & Platform event. The event, scheduled for June 6, 2024, from 8:00 to 10:00 a.m. ET, will spotlight three new programs emerging from the company's pre-clinical pipeline. These additions include two genetic disease initiatives aimed at vascular malformations and Fabry disease, and a potentially groundbreaking NRAS-specific inhibitor for precision oncology.

The vascular malformations program targets rare syndromes caused by unusual developments in lymphatic and blood vessels that lead to abnormal blood flow, sometimes resulting in severe or life-threatening conditions. These malformations can manifest as venous, cerebral cavernous, lymphatic malformations, or as part of the PIK3CA-related overgrowth spectrum. Relay's approach focuses on a mutant-selective PI3Kα inhibitor, presenting a promising potential for improved efficacy and better chronic tolerability. Clinical trials for this initiative are expected to commence in the first quarter of 2025, with an estimated 170,000 affected individuals in the U.S.

Fabry disease, a rare genetic disorder impacting approximately 8,000 people in the U.S., is marked by the body's inability to produce sufficient alpha-galactosidase A (αGal), leading to harmful Gb3 accumulation in cells and tissues. Relay’s pioneering non-inhibitory chaperone is designed to stabilize the αGal protein, enhancing Gb3 clearance without inhibiting enzyme activity. This therapeutic approach could offer chronic treatment options, whether as monotherapy or in combination with enzyme replacement therapy. Clinical trials for the Fabry disease program are slated for the second half of 2025.

The third major program focuses on creating a selective inhibitor for NRAS, a vital oncogene involved in various cancers, including melanoma, colorectal cancer, and non-small-cell lung cancer. The NRAS-selective inhibitor aims to address the limitations of current pan-RAS treatments by specifically targeting NRAS while sparing KRAS and HRAS, potentially reducing off-target toxicity and improving treatment efficacy. Clinical trials are anticipated to begin in the second half of 2025, targeting an estimated 28,000 patients diagnosed annually in the U.S. with NRAS-mutated solid tumors.

Relay Therapeutics, since its inception in 2016, has utilized its Dynamo™ platform to advance its drug discovery efforts, blending computational and experimental technologies. The company has successfully pushed several programs into clinical stages, with ambitions to start its first Phase 3 study of RLY-2608 next year. The Dynamo platform has been instrumental in generating eight drug candidates and filing four Investigational New Drug (IND) applications. Relay's future plans include launching three new clinical programs by the end of 2025, expanding their focus from precision oncology to genetic diseases and beyond.

Financially, Relay Therapeutics maintains steady cash guidance, expecting to fund operations into the second half of 2026 with current cash and investments totaling approximately $750 million as of March 31, 2024. The introduction of these new programs has been factored into existing financial forecasts, ensuring no changes to the cash runway.

Relay Therapeutics' New Program & Platform event aims to highlight the company's strides in transforming the drug discovery landscape. By leveraging the Dynamo platform, Relay is poised to continue its growth and make significant contributions to precision medicine, ultimately aiming to deliver life-changing therapies to patients.